Taxane particles and their use
US-11123322-B2 · Sep 21, 2021 · US
Glucocorticoid “nintedanib” particles and their use
US11931368B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11931368-B2 |
| Application number | US-201816650961-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 28, 2018 |
| Priority date | Sep 29, 2017 |
| Publication date | Mar 19, 2024 |
| Grant date | Mar 19, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed herein are particles of at least 95% by weight of a glucocorticoid that have a specific surface area of at least 10 m 2/g, methods for making, such particles, and methods for their use as therapeutics. Also disclosed herein are particles of at least 95% by weight of an indolinone that have a specific surface area of at least 10 m 2 /g, methods for making such particles, and methods for-their use as therapeutics.
First claim
Opening claim text (preview).
We claim: 1. A composition comprising nintedanib particles, wherein the nintedanib particles are at least 99% nintedanib by weight, or a pharmaceutically acceptable salt thereof, wherein the nintedanib particles have a specific surface area (SSA) of between 9 m 2 /g and about 20.14 m 2 /g, wherein the nintedanib particles are not bound to or conjugated to any other substance, and wherein the nintedanib particles have a volume-mean particle size between about 0.5 μm and about 5.0 μm. 2. The composition of claim 1 , wherein the nintedanib comprises nintedanib esylate. 3. The composition of claim 1 , wherein the composition is present in a suspension that further comprises a pharmaceutically acceptable aqueous carrier. 4. The composition of claim 1 , wherein the composition is a dry powder for inhalation. 5. The composition of claim 1 , wherein the nintedanib particles have a specific surface area (SSA) of between 9.94 m 2 /g and 20.14 m 2 /g. 6. The composition of claim 1 , wherein the nintedanib particles have a specific surface area between 11.05 m 2 /g and about 20.14 m 2 /g. 7. The composition of claim 1 , wherein the nintedanib particles are aerosolized and aerosol droplets of the nintedanib particles have a MMAD of between about 0.5 μm to about 6 μm diameter. 8. The composition of claim 6 , wherein the nintedanib particles are aerosolized and aerosol droplets of the nintedanib particles have a MMAD of between about 0.5 μm to about 6 μm diameter.
Assignees
Inventors
Classifications
- A61K31/569Primary
substituted in position 17 alpha, e.g. ethisterone · CPC title
for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles · CPC title
resulting in pure drug agglomerate optionally containing up to 5% of excipient · CPC title
Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title
Drugs for disorders of the cardiovascular system · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11931368B2 cover?
- Disclosed herein are particles of at least 95% by weight of a glucocorticoid that have a specific surface area of at least 10 m 2/g, methods for making, such particles, and methods for their use as therapeutics. Also disclosed herein are particles of at least 95% by weight of an indolinone that have a specific surface area of at least 10 m 2 /g, methods for making such particles, and methods f…
- Who is the assignee on this patent?
- Crititech Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/569. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).